Baltimore's $152m opioid settlement tossed – mayor slams corporate greed
A Supreme Court of Maryland ruling has effectively gutted Baltimore’s long-fought battle against opioid manufacturers, dismissing a $152 million settlement awarded in August 2025.
A bitter blow for the city
The initial verdict, after a judge slashed a proposed $266 million award, stemmed from a protracted legal struggle against pharmaceutical giants McKesson and Cencora (formerly AmerisourceBergen). Now, the city faces a significant setback, with the case remanded back to the Baltimore City Circuit Court.
Mayor Scott’s statement delivered a scathing rebuke. He argues that the state’s decision – prioritizing federal fines over local recourse – represents a betrayal of communities ravaged by the opioid crisis. ‘These corporations put profits over people,’ he asserted, a sentiment reflecting the deep-seated anger felt across the city.
But the story doesn’t end there. Before this latest turn, Baltimore had already secured approximately $580 million from multiple companies through similar lawsuits, largely stemming from allegations of deliberately fueling the crisis by flooding pharmacies with suspiciously high volumes of painkillers. The city’s meticulous plan, outlined in its 2025-2027 Opioid Restitution Fund strategy, aimed to leverage this funding – intended to reduce fatal overdoses by 50% within fourteen years – to expand Naloxone access, bolster mobile treatment options, and strengthen harm reduction programs.
The Supreme Court’s ruling, however, casts a shadow over those ambitious goals. Chief Justice Fader offered no explanation for the decision, leaving the future of the settlement – and the city’s efforts to combat the crisis – uncertain. Legal experts are already dissecting the ruling, anticipating a potential appeal from Baltimore.
A history of litigation
Baltimore’s pursuit of accountability against pharmaceutical companies has been a relentless campaign, marked by numerous settlements reached prior to Friday’s outcome. The city’s legal strategy centered on demonstrating that these companies knowingly contributed to the scale of the opioid epidemic by failing to adequately monitor and restrict the distribution of addictive painkillers.
The $152 million, originally awarded, was earmarked to specifically address the immediate impact of the crisis. It represented a tangible, albeit delayed, victory in a battle that has spanned years and claimed countless lives. Now, with the settlement potentially invalidated, the challenge remains: how to effectively protect Baltimore’s residents from the ongoing devastation of the opioid crisis.
The situation underscores a broader frustration – a feeling that corporate negligence is rarely held accountable, leaving local governments to shoulder the burden of mitigating the consequences. It’s a stark reminder that the fight against addiction is far from over, and that Baltimore’s resilience will be tested once more.